Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Quality Chemical Industries makes and sells medicines in Uganda, mainly antimalarial and antiretroviral drugs, and is one of Africa's few WHO-approved makers of these treatments.
Quality Chemical Industries is a Ugandan drugmaker that makes the medicines that fight two of Africa's biggest killers: malaria and HIV. It produces antimalarial pills and antiretroviral tablets, plus a fast-dissolving version of the malaria drug that patients can take without water, which matters a lot when someone is very sick. It sells these mostly to governments and to big global health buyers like the Global Fund and the U.S. government's PEPFAR program, often working through the nonprofit Clinton Health Access Initiative on supply deals.
The company got its start in the mid-2000s as a joint venture backed by Ugandan investors and the Indian drugmaker Cipla, which gave it the know-how and the formulas. Headquartered in Luzira, a neighborhood of Kampala, it became one of the few manufacturers in sub-Saharan Africa to win WHO prequalification — the stamp of approval that lets a drugmaker sell to international agencies and donors. That approval is the whole game: it is hard to get, expensive to keep, and it opens the door to the large public health budgets that pay for these drugs. Why would anyone buy from a Ugandan factory instead of a giant Indian or Chinese one? Proximity and pride matter. Local production cuts the long, fragile supply chain and shortens the wait for medicine to reach clinics. Being in the country also earns goodwill from the government, which wants a domestic supply of life-saving drugs. The catch is that the company is small and dependent on a handful of big buyers, so a single canceled order or a budget cut at the Global Fund can swing its fortunes. Its reliance on donor-funded public health spending is both the reason it exists and its biggest weakness.
In 1997, Uganda's government stopped importing and selling veterinary medicines, leaving a gap that six founders, including Emmanuel Katongole and George Baguma, set out to fill with Quality Chemicals Limited. They built a program that sold animal drugs directly to farmers, then moved into human health by importing ARVs from the Indian drugmaker Cipla as its agent in Uganda. Importing worked, but it left them at the mercy of supply and price shocks from abroad. So the board made a bold call: stop just buying medicines and start making them at home, a vision that became QCIL.
In 2005, Quality Chemical Industries Limited was registered as an equal partnership between Cipla and QCL. The Ugandan government chipped in land in Luzira, roads, power, water and a promise to buy the output, while Cipla brought the know-how. The plant was built to WHO standards, and it became the foundation for something no site in Africa had achieved before.
The big payoff for building to those standards arrived when QCIL's facility and its products, including ARVs and antimalarials, won WHO prequalification, the first such certification for a site in the region. That stamp of approval let global health organizations buy from QCIL, and it made the company the first African manufacturer to supply ACTs to the Global Fund. The gamble on local manufacturing had turned into real business.
QCL handed 14.45 percent of its shares to Cipla, giving the Indian company majority ownership, and the business was renamed Cipla Quality Chemical Industries Limited to match. Emmanuel Katongole moved up to executive chairman. The partnership that started as a 50-50 joint venture now had a clear boss.
In 2018, the company offered 18 percent of its shares to individual and institutional investors and listed on the Uganda Securities Exchange under the ticker QCIL. The listing spread ownership more widely and raised money for expansions, including a new warehouse and a quality control lab. For a moment, it looked like a coming-of-age story.
The coming-of-age story hit a wall fast. By mid-2019 the share price had fallen about 49 percent from its IPO price, trading was thin and earnings were weak. Profit after tax dropped 84.8 percent to $1.79 million for the year to March 2019, with total sales down to $51.4 million, because Global Fund procurement orders had fallen sharply. The market got a hard lesson in how much of this business depended on a few big buyers.
In November 2023, Africa Capitalworks SSA 3 acquired Cipla's controlling 51.18 percent stake, ending Cipla's majority ownership. The company reverted to its original name, Quality Chemical Industries Limited. After years under an Indian parent, it was now standing on its own.
In February 2024, the company formally changed its name back to Quality Chemical Industries Limited. The rebrand was more than a new label: it marked independence from Cipla under new majority control by Africa Capitalworks.
In 2026, QCIL posted its strongest financial year yet: revenue rose 8.8 percent to UShs 290.5 billion and profit after tax rose 38.8 percent to UShs 56.4 billion. It completed a hydroxyurea plant, making it the only manufacturer of sickle-cell therapy on the continent, launched 15 new private market products, and began building a new Luzira facility to double capacity and add injectables. The board did caution that the year got a boost from one-off items, including recovery of impaired Zambia receivables, and expected near-term margin pressure from heightened global competition.
Quality Chemical is listed on the Uganda Securities Exchange, which lets it raise capital from the public and gives Ugandans a way to own a piece of their country's medicine cabinet. The business of making essential drugs is steady but unglamorous — low margins, tight regulation, and constant pressure to keep prices down. Yet it occupies a niche that matters a great deal: a homegrown African manufacturer supplying the treatments that keep millions of people alive.
Saved answer · last researched 4 Nov 2026